Bryostatin 1-activated T cells can traffic and mediate tumor regression

Todd M. Tuttle, Kevin P. Bethke, Thomas H. Inge, Carl W. McCrady, George Pettit, Harry D. Bear

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Adoptive immunotherapy in humans may be limited by the lack of autologous tumor cells to activate and expand tumor-specific T cells. Pharmacologic manipulation of protein kinase C (PKC) and intracellular calcium may substitute for tumor antigen and stimulate T cells for adoptive immunotherapy. In the present study, we evaluated the ability of the PKC activator Bryostatin 1 (B) plus the calcium ionophore ionomycin (I) to activate lymphocytes obtained from popliteal lymph nodes (DLN) draining an MCA-105 footpad tumor. The adoptive transfer of B/I-stimulated DLN cells eradicated MCA-105 pulmonary metastases. These lymphocytes do not require concomitant IL-2 administration to mediate regression of lung metastases. Three days after intrasplenic injection of tumor cells and splenectomy, mice were given iv injections of B/I-stimulated DLN cells. Adoptive immunotherapy with these cells induced regression of established liver metastases. In an intradermal tumor model, the adoptive transfer of B/I-stimulated MCA-105 DLN cells cured mice of MCA-105 intradermal (id) tumors, but did not induce regression of MCA-203 tumors. Mice cured of MCA-105 id tumors were protected against MCA-105, but not MCA-203, tumor challenge in the footpad 7 weeks after adoptive immunotherapy.

Original languageEnglish (US)
Pages (from-to)543-548
Number of pages6
JournalJournal of Surgical Research
Volume52
Issue number6
DOIs
StatePublished - Jun 1992

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Bryostatin 1-activated T cells can traffic and mediate tumor regression'. Together they form a unique fingerprint.

  • Cite this